These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 32754263)

  • 1. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
    Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
    Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
    [No Abstract]   [Full Text] [Related]  

  • 2. Sirtuin-mediated deacetylation of hnRNP A1 suppresses glycolysis and growth in hepatocellular carcinoma.
    Yang H; Zhu R; Zhao X; Liu L; Zhou Z; Zhao L; Liang B; Ma W; Zhao J; Liu J; Huang G
    Oncogene; 2019 Jun; 38(25):4915-4931. PubMed ID: 30858544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.
    Jia G; Wang Y; Lin C; Lai S; Dai H; Wang Z; Dai L; Su H; Song Y; Zhang N; Feng Y; Tang B
    J Exp Clin Cancer Res; 2021 Sep; 40(1):299. PubMed ID: 34551796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAM68 promotes tumorigenesis in lung adenocarcinoma by regulating metabolic conversion via PKM alternative splicing.
    Zhu S; Chen W; Wang J; Qi L; Pan H; Feng Z; Tian D
    Theranostics; 2021; 11(7):3359-3375. PubMed ID: 33537092
    [No Abstract]   [Full Text] [Related]  

  • 5. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
    Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
    Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.
    Xu SH; Zhu S; Wang Y; Huang JZ; Chen M; Wu QX; He YT; Chen D; Yan GR
    Cell Death Dis; 2018 May; 9(5):479. PubMed ID: 29706618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
    Tu K; Yang W; Li C; Zheng X; Lu Z; Guo C; Yao Y; Liu Q
    Mol Cancer; 2014 May; 13():110. PubMed ID: 24884509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
    Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
    PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
    Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
    Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.
    Zhang Y; Tao R; Wu SS; Xu CC; Wang JL; Chen J; Yu YS; Tang ZH; Chen XH; Zang GQ
    J Exp Clin Cancer Res; 2018 Jun; 37(1):116. PubMed ID: 29898761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MARCH5 promotes hepatocellular carcinoma progression by inducing p53 ubiquitination degradation.
    Cai X; Gao J; Yan Z; Zhang H; Guo D; Zhang S
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):303. PubMed ID: 38861187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFβ Signaling.
    Chen J; Mitra A; Li S; Song S; Nguyen BN; Chen JS; Shin JH; Gough NR; Lin P; Obias V; He AR; Yao Z; Malta TM; Noushmehr H; Latham PS; Su X; Rashid A; Mishra B; Wu RC; Mishra L
    Cancer Res; 2020 May; 80(9):1819-1832. PubMed ID: 32127355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma.
    Li X; Yuan J; Song C; Lei Y; Xu J; Zhang G; Wang W; Song G
    Cell Death Differ; 2021 Aug; 28(8):2315-2332. PubMed ID: 33649471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
    Liu AM; Xu Z; Shek FH; Wong KF; Lee NP; Poon RT; Chen J; Luk JM
    PLoS One; 2014; 9(1):e86872. PubMed ID: 24466275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
    Chen Z; Lu X; Wang Z; Jin G; Wang Q; Chen D; Chen T; Li J; Fan J; Cong W; Gao Q; He X
    Oncotarget; 2015 Feb; 6(4):2538-48. PubMed ID: 25576919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma.
    Tan HW; Leung CO; Chan KK; Ho DW; Leung MS; Wong CM; Ng IO; Lo RC
    Int J Cancer; 2019 Oct; 145(7):1860-1873. PubMed ID: 30834518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PKM2 promotes glucose metabolism through a let-7a-5p/Stat3/hnRNP-A1 regulatory feedback loop in breast cancer cells.
    Yao A; Xiang Y; Si YR; Fan LJ; Li JP; Li H; Guo W; He HX; Liang XJ; Tan Y; Bao LY; Liao XH
    J Cell Biochem; 2019 Apr; 120(4):6542-6554. PubMed ID: 30368881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARHGAP24 represses β-catenin transactivation-induced invasiveness in hepatocellular carcinoma mainly by acting as a GTPase-independent scaffold.
    Yang W; Wang B; Yu Q; Liu T; Li T; Tian T; Jin A; Ding L; Chen W; Wang H; Xian J; Pan B; Zhou J; Fan J; Yang X; Guo W
    Theranostics; 2022; 12(14):6189-6206. PubMed ID: 36168627
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
    Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
    EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
    Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.